top of page

Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody..

– Preclinical data show VIR-2482 has broad neutralizing potential against all major strains of influenza A from the last 100 years –

– Extended half-life observed in Phase 1 demonstrates potential for once-per-season dosing –

– Claims-based analysis highlights the high hospitalization rates and elevated costs among high-risk elderly patients, reinforcing need for new approaches to prevention –

Download • 98KB


bottom of page